Upcoming Earnings: Q2 '26
Estimated EPS
-$0.22
Estimated Rev
$18.89M
• Reported GAAP EPS of -$0.11 up 78.00% YoY • Reported revenue of $19.25M up 2.17% YoY
Bullish Takeaway
ADC Therapeutics achieved the primary endpoint in the LOTIS-5 trial and completed enrollment for the LOTIS-7 trial, supporting potential Breakthrough Designation submissions and anticipated revenue growth starting in the year 2027.
Bearish Takeaway
ADC Therapeutics faces regulatory uncertainty following FDA concerns regarding the LOTIS-5 trial benefit-risk profile, alongside a 17 percent workforce reduction and a significant year-over-year decline in license revenue and royalties.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.22 | -- | -- | N/A |
Q1 '26 | -$0.20 | -$0.21 | -4.13% | MISSED |
Q4 '25 | -$0.27 | -$0.04 | 85.09% | BEAT |
Q3 '25 | -$0.36 | -$0.30 | 17.43% | BEAT |
Q2 '25 | -$0.49 | -$0.50 | -1.63% | MISSED |